Adam Pfefferle

Assistant Professor

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Background: Treatment approaches differ for isolated in-breast tumor recurrence (representing treatment failure) and new primary breast tumors (representing high etiologic risk). However, methods for distinguishing recurrences from second primaries (based on radiographic and histologic criteria) are subject to error. Gold-standard genomic datasets for assessing classification accuracy have been lacking. Methods: To identify the scope of misclassification, we performed DNA sequencing of 1,200 genes in 108 participants with synchronous or metachronous second breast cancer in the Carolina Breast Cancer Study (CBCS3). DNA sequencing data included 87 second tumors and 42 paired first and second breast cancers in the same patient (14 contralateral and 28 ipsilateral). Recurrence status was classified based on mutations and copy number, accounting for site-specific mutation probabilities. DNA-based recurrence versus second primary classifications were compared with clinical and Surveillance, Epidemiology and End Results (SEER) classifications based on laterality, histology, quadrant, and latency. Results: Twenty-two of 28 ipsilateral tumor pairs (79%) shared at least one mutation and were classified as recurrences. Pathologist classifications of ipsilateral second tumors were 79% accurate [95% confidence interval (CI), 60%–90%) with higher sensitivity (95%, 95% CI = CI, 78%–99%) and lower specificity (17%, 95% CI, 3%–56%). SEER classifications were 82% accurate (95% CI, 64%–92%) with lower sensitivity (77%, 95% CI, 57%–90%) and higher specificity (100%, 95% CI, 61%–100%). Conclusions: Although most genomically defined recurrences are captured by clinical recurrence definitions, new primaries are frequently misclassified. Impact: Given overtreatment harms, genomic methods may support treatment de-escalation for second breast cancers.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background: Treatment approaches differ for isolated in-breast tumor recurrence (representing treatment failure) and new primary breast tumors (representing high etiologic risk). However, methods for distinguishing recurrences from second primaries (based on radiographic and histologic criteria) are subject to error. Gold-standard genomic datasets for assessing classification accuracy have been lacking. Methods: To identify the scope of misclassification, we performed DNA sequencing of 1,200 genes in 108 participants with synchronous or metachronous second breast cancer in the Carolina Breast Cancer Study (CBCS3). DNA sequencing data included 87 second tumors and 42 paired first and second breast cancers in the same patient (14 contralateral and 28 ipsilateral). Recurrence status was classified based on mutations and copy number, accounting for site-specific mutation probabilities. DNA-based recurrence versus second primary classifications were compared with clinical and Surveillance, Epidemiology and End Results (SEER) classifications based on laterality, histology, quadrant, and latency. Results: Twenty-two of 28 ipsilateral tumor pairs (79%) shared at least one mutation and were classified as recurrences. Pathologist classifications of ipsilateral second tumors were 79% accurate [95% confidence interval (CI), 60%–90%) with higher sensitivity (95%, 95% CI = CI, 78%–99%) and lower specificity (17%, 95% CI, 3%–56%). SEER classifications were 82% accurate (95% CI, 64%–92%) with lower sensitivity (77%, 95% CI, 57%–90%) and higher specificity (100%, 95% CI, 61%–100%). Conclusions: Although most genomically defined recurrences are captured by clinical recurrence definitions, new primaries are frequently misclassified. Impact: Given overtreatment harms, genomic methods may support treatment de-escalation for second breast cancers.

Year:

2026

Year:

2025

PURPOSE For hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard of care. They are also used after progression on first-line aromatase inhibitors (AIs), but some patients may respond better to chemotherapy-based options. We examined tumor features associated with survival from GEICAM/2013-02 PEARL, a phase III trial of palbociclib + ET versus capecitabine in AI-resistant HR+/HER2– MBC. METHODS For 158 and 155 patients from each arm, 878 previously published gene expression signatures were derived using RNA sequencing on pretreatment tumor specimens, both primary and metastatic. Multivariable Cox models for progression-free survival (PFS) and overall survival (OS) were constructed with 16 preselected signatures related to proliferation, loss of retinoblastoma, and immune infiltration, and via Elastic Net using all signatures. RESULTS Significant PFS difference by PAM50 intrinsic subtype was observed with palbociclib + ET. Comparing treatment arms, luminal A subtype trended toward longer PFS with palbociclib + ET, and luminal B and nonluminal subtypes had significantly longer PFS with capecitabine. Three B-cell (B-lymphocyte)–associated signatures correlated with shorter OS with palbociclib + ET. The immune-activated Immune1 TCGA breast cancer signature had significant treatment arm interaction for OS. Elastic Net iteratively selected B-cell–associated signatures independently associated with shorter OS with palbociclib + ET. CONCLUSION PAM50 intrinsic subtype predicted PFS differences between palbociclib + ET and capecitabine. Lower B-cell–associated gene expression predicted longer OS with palbociclib + ET versus capecitabine. These features may help identify HR+/HER2– tumors resistant to further ET-based treatment with CDK4/6i.

Year:

2025

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage II-III TNBC tumors with paired RNA and DNA sequencing data from the CALGB 40603 (Alliance) clinical trial, along with 448 stage II-III TNBC tumors with paired RNA and DNA data from three additional datasets. We identify DNA mutations associated with RNA-based subtypes, specific TP53 missense mutations compatible with potential neoantigen activity, and a consistently highly altered copy number landscape. We train exploratory multi-modal elastic net models of TNBC patient overall survival to determine the added impact of DNA-based features to RNA and clinical features. We find that mutations and copy number show little to no prognostic value, while RNA expression features, including signatures of T cell and B cell activity, along with stage, improve stratification of TNBC survival risk.

Year:

2025

Background: Heterogeneity within triple-negative breast cancer (TNBC) makes it challenging to target therapeutically. Despite recent advances in the standard of care treatment of stage II-III TNBC, which now includes multiple chemotherapeutic agents plus an immune checkpoint inhibitor, the cure rate for these patients remains suboptimal. There is still a critical need for improved molecular characterization of TNBC and the development of accurate prognostic tools to assist in making treatment escalation and de-escalation decisions. Here, we present an analysis of the DNA and RNA landscape in a set of patients treated on a clinical trial and validation of molecular and prognostic features using three additional data sets. Methods: CALGB 40603 (Alliance) is a randomized phase II trial that evaluated the impact of adding carboplatin and/or bevacizumab to standard anthracycline/taxane neoadjuvant chemotherapy in stage II-III TNBC. Targeted panel DNA sequencing of pre-treatment tumor samples from 238 patients enrolled in this study was performed and analyzed alongside matched pre-treatment RNAseq data. These results were then combined with clinical outcomes data to develop a prognostic multi-variable elastic net model of overall survival. We subsequently evaluated this model on samples from 380 stage II-III TNBC patients from three independent publicly available datasets. Results: Similar to other TNBC data sets, DNAseq results of 40603 identified TP53 (86%) as the most frequent somatically mutated gene, followed by MT-ND5 (16%), MT-ND4 (12%), CSMD3 (8%), and PIK3CA (7%). BRCA1 (germline 8%, somatic 4%), BRCA2 (germline 2%, somatic 0.4%), and PALB2 (germline 1%) gene mutations were also detected, and when combined into a single “homologous recombination deficiency” category totaled 15%. The DNA copy number landscape of TNBC was very similar across the four data sets, and largely mirrored the landscape seen for basal-like breast cancer characterized in TCGA. Importantly, only one somatically mutated gene (PIK3R2), and no DNA copy number altered regions, were associated with pathologic complete response or survival at a false discovery rate < 0.05. We next sought to use these multi-platform data to train a prognostic Cox elastic net regression model using CALGB 40603 data and a diverse set of features, including tumor stage, 804 RNA expression signatures, 727 genes with somatic mutations, and 534 chromosomal segment-level copy number alterations. This yielded a 31-feature prognostic model with C-index performance values (95% confidence interval) of 0.68 (0.66-0.69), 0.61 (0.59-0.63), and 0.83 (0.82-0.84) using FUSCC (PMID 30853353), METABRIC (PMID 22522925), and TCGA (PMID 23000897) test sets. The most heavily weighted features in this model were tumor stage and multiple immune signatures including an IgG signature, and this model had higher C-index values than a model trained using only tumor stage. Conclusions: This study provides a comprehensive and integrated characterization of the DNA- and RNA-based landscape of a large stage II-III TNBC patient data set. Through the development of a multi-omic elastic net model of TNBC survival, we show that we may improve the prognostic accuracy for overall survival beyond stage alone by incorporating machine learning selected molecular features. Furthermore, the model’s ability to identify good overall survival outcome patients when given neoadjuvant chemotherapy illustrates its potential utility for informing treatment escalation/de-escalation decisions, which could be clinically valuable if further validated. Support: U10CA180821, U10CA180882; U24CA176171; U10CA180888 (SWOG); P50-CA058223; Genentech; https://acknowledgments.alliancefound.org. Clinicaltrials.gov Id#: NCT00861705 Citation Format: Brooke Felsheim, Aranzazu Fernandez Martinez, Cheng Fan, Adam Pfefferle, Michele Hayward, Katherine Hoadley, Naim Rashid, Sara Tolaney, George Somlo, Lisa Carey, William Sikov, Charles Perou. Pai

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Collaborators (14)

Katherine Hoadley

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Manel Juan

Head of Immunology service/department

Hospital Clínic de Barcelona

SPAIN
View details

Jesse Raab

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Charles Perou

Professor

University of North Carolina

UNITED STATES
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Victoria Bae-Jump

Professor and Associate Division Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

Aranzazu Fernandez-Martinez

University of North Carolina, Lineberger Comprehensive Cancer Center

UNITED STATES
View details

Benjamin Calhoun

Associate Professor

University of North Carolina

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Michael Love

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Sarah Van Alsten

University of North Carolina at Chapel Hill

UNITED STATES
View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN
View details

Xavier Gonzàlez Farré

Associate professor

Universitat Internacional de Catalunya

SPAIN
View details

David Corcoran

Assistant Professor

University of North Carolina

UNITED STATES
View details